.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Julphar
Dow
Baxter
UBS
QuintilesIMS
Cipla
Chubb
Fuji

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,822,499

« Back to Dashboard

Details for Patent: 8,822,499

Title:Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Inventor(s): Jaworsky; Markian S. (Hopewell, NJ), Chen; Roger Shen-Chu (Edison, NJ), Muller; George W. (Rancho Santa Fe, CA), Saindane; Manohar T. (Monmouth Junction, NJ), Cameron; Louise M. (East Windsor, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Sep 22, 2011
Application Number:13/240,686
Claims:1. A polymorphic mixture of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione comprising crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate is present at greater than about 97% by weight of the polymorphic mixture.

2. A polymorphic mixture of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione comprising crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate is present at greater than about 95% by weight of the polymorphic mixture.

3. A polymorphic mixture of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione comprising crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate is present at greater than about 90% by weight of the polymorphic mixture.

4. A polymorphic mixture of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione comprising crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate, wherein the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione dihydrate is present at greater than about 80% by weight of the polymorphic mixture.

5. The polymorphic mixture of any one of claims 1, 2, 3, and 4, wherein the dihydrate has an X-ray powder diffraction pattern comprising peaks at approximately 20, 24.5 and 29 degrees 2.theta..

6. The polymorphic mixture of any one of claims 1, 2, 3, and 4, wherein the dihydrate has an X-ray powder diffraction pattern comprising peaks at 20.0, 24.7 and 28.6 degrees 2.theta..

7. The polymorphic mixture of any one of claims 1, 2, 3, and 4, wherein the dihydrate loses about 12% by weight when heated from about 30.degree. C. to about 175.degree. C.

8. A pharmaceutical composition comprising the polymorphic mixture of any one of claims 1, 2, 3, and 4, and a pharmaceutically acceptable excipient, diluent, or carrier.

9. The pharmaceutical composition of claim 8, which is a capsule.

10. The pharmaceutical composition of claim 8, which is a tablet.

11. The pharmaceutical composition of claim 8, wherein the dihydrate is present in an amount of about 5 mg, about 10 mg, about 25 mg, or about 50 mg.

12. The pharmaceutical composition of claim 8, wherein the dihydrate is present in an amount of from about 0.1 mg to about 150 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
AstraZeneca
Accenture
McKesson
Chinese Patent Office
Cerilliant
Johnson and Johnson
Mallinckrodt
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot